145 related articles for article (PubMed ID: 12908663)
1. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs.
Rosenheck R; Doyle J; Leslie D; Fontana A
Schizophr Bull; 2003; 29(1):81-93. PubMed ID: 12908663
[TBL] [Abstract][Full Text] [Related]
2. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
Essock SM; Frisman LK; Covell NH; Hargreaves WA
Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Allan E; Erdos J; Frisman LK; Xu W; Thomas J; Henderson W; Charney D
Arch Gen Psychiatry; 1999 Jun; 56(6):565-72. PubMed ID: 10359474
[TBL] [Abstract][Full Text] [Related]
5. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
9. Did CATIE influence antipsychotic use?
Citrome L; Jaffe A; Martello D; Allingham B; Levine J
Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
[No Abstract] [Full Text] [Related]
10. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
11. The Business Case for Expanded Clozapine Utilization.
Gören JL; Rose AJ; Smith EG; Ney JP
Psychiatr Serv; 2016 Nov; 67(11):1197-1205. PubMed ID: 27301766
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
13. Cost of the Illness of Treatment-Resistant Schizophrenia: A Mirror Image Study Comparing Clozapine With Other Antipsychotics.
Verma M; Grover S; Chakrabarti S
J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):36-44. PubMed ID: 33347021
[TBL] [Abstract][Full Text] [Related]
14. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
Ginsberg G; Shani S; Lev B
Pharmacoeconomics; 1998 Feb; 13(2):231-41. PubMed ID: 10178649
[TBL] [Abstract][Full Text] [Related]
15. Risperidone versus haloperidol: II. Cost-effectiveness.
Davies A; Langley PC; Keks NA; Catts SV; Lambert T; Schweitzer I
Clin Ther; 1998; 20(1):196-213. PubMed ID: 9522115
[TBL] [Abstract][Full Text] [Related]
16. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
18. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
Amin S
Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
[TBL] [Abstract][Full Text] [Related]
20. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Ganguly R; Miller LS; Martin BC
Schizophr Res; 2003 Sep; 63(1-2):111-9. PubMed ID: 12892865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
